Immunogenicity Testing Services

Pioneering Expertise in ADA Assessment, NAb Assays, and Isotyping

As a world-leading authority in the field of immunogenicity testing, BioAgilytix understands the complexities that must be addressed in Anti-Drug Antibodies analysis, Neutralizing Antibody (NAb) assay development and validation, isotyping, and more. Our experts will help you determine the optimal method for immunogenicity assessment, and select the optimal analytical equipment platform to yield high-quality data results.

Find Answers to Your Immunogenicity Testing Questions:

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.

Immunogenicity Testing: Key To
Assessing Drug Safety And Efficacy

Immunogenicity is a significant concern for biologic drugs as it can affect both safety and efficacy. The consequences of product immunogenicity vary from no evidence of clinical effect to severe, life-threatening responses. Therefore the assessment of undesirable immunogenicity of therapeutic proteins and peptides is a key element in biological drug development. In the context of immune-mediated adverse effects of biological drugs, it is critical to understand the interplay of the adaptive and innate immune responses.

In recent years, there has been growing consensus regarding the data needed to assess product immunogenicity. Understanding the incidence, kinetics and magnitude of Anti-Drug Antibodies, its neutralizing ability, cross-reactivity with endogenous molecules or other marketed biologic drugs, and the related clinical impact, may enhance clinical management of patients treated with biologic drugs.

Recent Aspects and Challenges in the Assessment of Immunogenicity

Dr. Arno Kromminga discusses the emerging technologies that are making analytical and clinical data interpretation of immunogenicity more challenging, and the issues that must be addressed in the comparative immunogenicity analysis of an innovative therapeutic and biosimilar.

BioAgilytix Immunogenicity Services: Applying A Tiered Approach

Our team’s scientific, medical, and technical expertise supports all aspects to assess this key aspect for the approval of the protein drugs. We understand that the measurement of adverse immune reactions is complex as it depends on many drug- and disease-specific aspects. The selection of appropriate assays and an assay strategy has to be selected specifically for each project. A generic approach for the assessment of immunogenicity is not feasible. Challenges in appropriate assay selection include the evaluation of the presence of anti-drug antibodies prior to the initiation of the treatment (pre-existing antibodies) or cross-reactivity of ADA of different isotypes.

Immunogenicity data are interpreted in the context of PK and PD data, but the clinical manifestations of the patients also must be taken into account. Sometimes the loss or reduction of drug efficacy can be observed after a long period of time, measured by disease activity scores or by MRI or other clinical parameters.

Therefore, ADA should not only be measured during drug development in pre-clinical or clinical studies, but also post-approval as a routine monitoring parameter in specialized clinical laboratories.

The cascade of immunogenicity testing is performed following a tiered approach starting with a screening assay, followed by a confirmatory assay and characterization assay.

  • ADA Immunogenicity Assay Analysis
  • ADA Characterization
  • NAb Analysis

Optimal Platforms For Immunogenicity Assessment: Sensitivity Is Key

The assessment of immunogenicity can leverage a variety of analytical equipment platforms. Each of these platforms possesses unique strengths, weaknesses and therefore, optimal uses. BioAgilytix has experience immunogenicity assay development across the bioanalytical lifecycle requiring high drug tolerance levels. We can recommend strategies and provide contract services for assessing immunogenicity using a variety of technologies. The platforms we typically leverage are listed below.

ELISA

MSD-ECL

Gyrolab

Biacore

ImmunoCAP

Flow Cytometry
(FACS Analysis)

Luminex

Assessing the Immunogenicity of Antibody-Drug Conjugates

Immunogenicity and bioanalytical assessments are becoming more challenging as the immune system is exposed to more complex biologics. Learn more about this evolving topic in a recent article from one of our experts.

Your Project Will Benefit From Our World-Leading Immunogenicity Expertise

Our experts understand the complexities that must be addressed in immunogenicity testing, including isotyping, ADA analysis, NAb assays, and more, and will help you determine the optimal analytical equipment platform to yield high-quality data results. Specifically, our immunogenicity services include labeling of antibody reagents, ADA purification, and oversight of surrogate positive control antibody generation. Our scientists are experienced in supporting immunogenicity studies in a variety of species including rodents, humans, and non-human primates.

Our Immunogenicity Expertise Includes:
  • ADA
  • NAb Assays
  • Screening Assays
  • Confirmatory Assays
  • NK Cell Killing (Cytotoxicity)
  • Phagocytosis or Phagoburst™ (neutrophils and monocytes)
  • Characterization Assays
  • Antibody Generation
  • Isotyping
  • T-Cell Proliferation
  • Individual and Multiplex Cytokine Analysis
  • Cytokine Release Syndrome (Cytokine Storm)

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Pharmacokinetics & Pharmacodynamics (PK/PD)

    See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.